Free Trial
NASDAQ:TPST

Tempest Therapeutics Q1 2025 Earnings Report

Tempest Therapeutics logo
$6.30 -0.36 (-5.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.36 +0.07 (+1.03%)
As of 07/18/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tempest Therapeutics EPS Results

Actual EPS
-$3.16
Consensus EPS
-$3.71
Beat/Miss
Beat by +$0.55
One Year Ago EPS
N/A

Tempest Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tempest Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Tempest Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tempest Therapeutics Earnings Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
TPST Tempest Therapeutics, Inc. - Seeking Alpha
See More Tempest Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email.

About Tempest Therapeutics

Tempest Therapeutics (NASDAQ:TPST) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies in oncology. The company’s research portfolio encompasses both immuno-oncology and precision oncology programs designed to modulate key cancer pathways and enhance anti-tumor immune responses. Lead assets include inhibitors targeting metabolic and signaling pathways that support tumor growth and immune evasion, with multiple candidates advancing through preclinical and early clinical studies.

Founded in 2016 and headquartered in Watertown, Massachusetts, Tempest operates research facilities in the United States and maintains corporate offices in Dublin, Ireland. The dual structure allows the company to leverage U.S.-based scientific talent and Irish incorporation benefits. Tempest collaborates with academic institutions, contract research organizations, and strategic partners to accelerate drug discovery and clinical development, maintaining a pipeline that addresses solid tumors and hematologic malignancies.

Under the leadership of President and Chief Executive Officer Mark McCamish, Tempest has built a management team with extensive experience in oncology drug development and regulatory strategy. The executive team includes seasoned professionals in clinical operations, chemistry manufacturing and controls (CMC), and business development, enabling streamlined advancement of programs from discovery through proof-of-concept trials. The board of directors features industry veterans who guide corporate strategy and governance.

Tempest Therapeutics is committed to translating cutting-edge science into therapies that improve outcomes for cancer patients. By focusing on innovative mechanisms of action and precision patient selection, the company aims to address unmet medical needs and deliver differentiated treatment options. With a growing pipeline and strategic partnerships, Tempest continues to position itself as a dynamic player in the oncology landscape.

View Tempest Therapeutics Profile

More Earnings Resources from MarketBeat